Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe C Ornstein

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Clinical Genitourinary Cancer|January 20, 2024
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse EventsAmanda Nizam, Ryan K Rader, Alice Tzeng, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Targeted Oncology|July 15, 2020
Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and PrednisoneIris Y Sheng, Jaleh Fallah, Ruby Gupta, et al.
Patient Preference and Adherence|August 20, 2024
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice ExperimentMoshe C Ornstein, Lisa C Rosenblatt, Xin Yin, et al.
Urology|May 29, 2025
Safety of Partial and Radical Nephrectomy for Complex Locally Advanced Renal Cell Carcinoma After Neo-Adjuvant Immune Checkpoint Inhibition: Analysis From a Phase 1b Trial (Durvalumab +/- Tremelimumab)Jason M Scovell, Brian I Rini, Venkatesh Krishnamurthi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaMoshe C Ornstein, Laura S Wood, Paul Elson, et al.
Clinical Genitourinary Cancer|September 16, 2018
Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative SurgeryNima Almassi, Tianming Gao, Byron Lee, et al.
Journal for Immunotherapy of Cancer|October 19, 2018
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumabHaris Zahoor, Pedro C Barata, Xuefei Jia, et al.
Leukemia & Lymphoma|January 8, 2015
Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapyMoshe C Ornstein, Sudipto Mukherjee, Michael Keng, et al.
Clinical Genitourinary Cancer|March 3, 2019
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint InhibitorsMoshe C Ornstein, Cassandra Calabrese, Laura S Wood, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Clinical Genitourinary Cancer|January 20, 2024
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse EventsAmanda Nizam, Ryan K Rader, Alice Tzeng, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Targeted Oncology|July 15, 2020
Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and PrednisoneIris Y Sheng, Jaleh Fallah, Ruby Gupta, et al.
Patient Preference and Adherence|August 20, 2024
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice ExperimentMoshe C Ornstein, Lisa C Rosenblatt, Xin Yin, et al.
Urology|May 29, 2025
Safety of Partial and Radical Nephrectomy for Complex Locally Advanced Renal Cell Carcinoma After Neo-Adjuvant Immune Checkpoint Inhibition: Analysis From a Phase 1b Trial (Durvalumab +/- Tremelimumab)Jason M Scovell, Brian I Rini, Venkatesh Krishnamurthi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaMoshe C Ornstein, Laura S Wood, Paul Elson, et al.
Clinical Genitourinary Cancer|September 16, 2018
Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative SurgeryNima Almassi, Tianming Gao, Byron Lee, et al.
Journal for Immunotherapy of Cancer|October 19, 2018
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumabHaris Zahoor, Pedro C Barata, Xuefei Jia, et al.
Leukemia & Lymphoma|January 8, 2015
Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapyMoshe C Ornstein, Sudipto Mukherjee, Michael Keng, et al.
Clinical Genitourinary Cancer|March 3, 2019
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint InhibitorsMoshe C Ornstein, Cassandra Calabrese, Laura S Wood, et al.
Pageof 7